Phase III international multicenter randomized trial | ESPAC Group | n = 730 | Resected PDAC | Lancet 2017 **Neoptolemos et al.** John P. Neoptolemos Published in The Lancet, 2017 Enrollment: 2008–2014 [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/28129987/) --- ### Essential Takeaway ESPAC-4 demonstrated improved overall survival with adjuvant gemcitabine plus capecitabine compared with gemcitabine alone following PDAC resection. The trial established combination chemotherapy as superior to gemcitabine monotherapy and became the dominant adjuvant standard immediately prior to the emergence of mFOLFIRINOX. --- ### Clinical Question Does adjuvant gemcitabine plus capecitabine improve survival compared with gemcitabine alone after curative-intent resection of pancreatic ductal adenocarcinoma? --- ### Population - Resected PDAC - R0 or R1 resections - No metastatic disease - Adequate postoperative recovery for chemotherapy Both pancreatic head and body/tail tumors were included. --- ### Study Design #### Arm 1 — Gemcitabine Alone - 6 cycles gemcitabine #### Arm 2 — Gemcitabine + Capecitabine - 6 cycles gemcitabine - Concurrent oral capecitabine Treatment duration: - 24 weeks total --- ### Endpoints #### Primary Endpoint Overall survival (OS) #### Secondary Endpoints - Relapse-free survival (RFS) - Toxicity/adverse events - Treatment completion rates --- ### Key Results #### Overall Survival Combination therapy improved median OS: - 28.0 vs 25.5 months - HR 0.82 - p = 0.032 --- #### Long-Term Survival ##### 5-Year Overall Survival - 28.8% vs 16.3% Demonstrated meaningful long-term survival improvement with combination therapy. --- #### Relapse-Free Survival - 13.9 vs 13.1 months RFS differences were relatively modest despite the OS improvement. --- ### Toxicity Combination therapy increased: - diarrhea - hand-foot syndrome - neutropenia However, toxicity remained generally manageable and treatment completion rates were acceptable. --- ### Additional Findings #### Reinforced Systemic Nature of PDAC ESPAC-4 further supported the principle that intensified systemic therapy improves outcomes after resection. #### Transitioned the Field Beyond Gemcitabine Monotherapy The study established combination chemotherapy as preferable to single-agent gemcitabine for appropriately selected patients. --- ### Interpretation ESPAC-4 became one of the landmark modern adjuvant PDAC trials because it demonstrated that escalation beyond gemcitabine monotherapy could meaningfully improve survival after resection. The trial represented an important transition point between: - earlier gemcitabine-alone strategies - modern intensified multi-agent adjuvant regimens It also reinforced the importance of delivering systemic therapy after pancreatic resection whenever feasible. --- ### Important Limitations #### Modest Absolute Survival Difference Although statistically significant, median OS improvement was relatively moderate. #### Pre-mFOLFIRINOX Era The trial preceded PRODIGE-24 and modern mFOLFIRINOX standards. #### Toxicity Considerations Combination therapy increased gastrointestinal and hematologic toxicity compared with gemcitabine alone. #### No Neoadjuvant Component The study reflected a surgery-first era before widespread adoption of neoadjuvant strategies. --- ### Practice Impact ESPAC-4 established gemcitabine plus capecitabine as a preferred adjuvant regimen after PDAC resection and became the dominant adjuvant standard immediately before adoption of mFOLFIRINOX. The trial reinforced several major principles: - combination chemotherapy is superior to monotherapy - postoperative systemic therapy improves long-term survival - PDAC should be approached as a systemic disease even after curative-intent surgery ESPAC-4 also served as a key bridge between CONKO-era treatment and modern intensified perioperative strategies.